NCT05386758View on ClinicalTrials.gov

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

February 4, 2023

Study Completion Date

March 1, 2023

Conditions
Renal Impairment
Interventions
DRUG

Molnupiravir

Four 200 mg capsules administered orally as a single dose

Trial Locations (4)

19107

Thomas Jefferson University-Pharmacology, Physiology and Cancer Biology ( Site 0001), Philadelphia

33009

Velocity Clinical Research, Hallandale Beach ( Site 0005), Hallandale

33147

Advanced Pharma CR, LLC ( Site 0004), Miami

33603

Genesis Clinical Research, LLC ( Site 0003), Tampa

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY